- Home
- MP vs CRSP Comparison
MP vs CRSP Comparison
Compare MP & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MP
- CRSP
- Stock Information
- Founded
- MP 2017
- CRSP 2013
- Country
- MP United States
- CRSP Switzerland
- Employees
- MP N/A
- CRSP N/A
- Industry
- MP Metal Mining
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MP Basic Materials
- CRSP Health Care
- Exchange
- MP Nasdaq
- CRSP Nasdaq
- Market Cap
- MP 4.0B
- CRSP 3.3B
- IPO Year
- MP N/A
- CRSP 2016
- Fundamental
- Price
- MP $21.80
- CRSP $36.29
- Analyst Decision
- MP Buy
- CRSP Buy
- Analyst Count
- MP 9
- CRSP 16
- Target Price
- MP $23.61
- CRSP $73.07
- AVG Volume (30 Days)
- MP 5.9M
- CRSP 2.1M
- Earning Date
- MP 05-08-2025
- CRSP 05-06-2025
- Dividend Yield
- MP N/A
- CRSP N/A
- EPS Growth
- MP N/A
- CRSP N/A
- EPS
- MP N/A
- CRSP N/A
- Revenue
- MP $215,981,000.00
- CRSP $37,675,000.00
- Revenue This Year
- MP $44.19
- CRSP $26.79
- Revenue Next Year
- MP $70.76
- CRSP $297.32
- P/E Ratio
- MP N/A
- CRSP N/A
- Revenue Growth
- MP 4.63
- CRSP N/A
- 52 Week Low
- MP $10.02
- CRSP $30.04
- 52 Week High
- MP $29.72
- CRSP $67.88
- Technical
- Relative Strength Index (RSI)
- MP 50.05
- CRSP 46.12
- Support Level
- MP $18.64
- CRSP $35.38
- Resistance Level
- MP $20.77
- CRSP $38.13
- Average True Range (ATR)
- MP 1.15
- CRSP 1.73
- MACD
- MP 0.03
- CRSP -0.03
- Stochastic Oscillator
- MP 80.20
- CRSP 26.30
About MP MP Materials Corp.
MP Materials Corp is the producer of rare earth materials in the Western Hemisphere. The company owns and operates the Mountain Pass Rare Earth Mine and Processing Facility, the only rare earth mining and processing site of scale in North America.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.